Global Myasthenia Gravis Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
Global Myasthenia Gravis Treatment Market Introduction and Overview
According to SPER Market Research, the Global Myasthenia Gravis Treatment Market is estimated to reach USD 5.81 billion by 2034 with a CAGR of 9.25%.
The report includes an in-depth analysis of the Global Myasthenia Gravis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The global Myasthenia Gravis Treatment market was valued at USD 2.4 billion in 2024, and it is expected to rise at a 9.25% CAGR from 2025 to 2034. Myasthenia gravis treatment is being driven by advances in biotechnology, targeted biologic therapies, rising diagnosis rates, increased investment in orphan drugs, favorable regulations, expedited approvals, and an aging population that requires effective long-term management of autoimmune disorders. Meanwhile, the myasthenia gravis treatment industry is constrained by high treatment costs, insufficient reimbursement, limited healthcare infrastructure, lengthy regulatory approvals, and concerns about long-term safety and efficacy, which all limit accessibility, adoption, and consistent growth of therapies across regions.
By Treatment Type Insights
Medications can significantly suppress the immune system and effectively manage the resulting symptoms. Immunotherapies like Soliris (eculizumab) and corticosteroids, as well as immunosuppressive medicines like Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine), are used. The other primary treatment option is surgery, which is the most invasive and typically involves a thymectomy. The thymus deteriorates with age (thymic involution); nonetheless, full absence of the thymus will drastically decrease a patient's immunological response. The monoclonal antibodies segment had the biggest market share and is likely to keep its lead position during the projection period, owing to its high precision in treating myasthenia gravis and improved effectiveness.
By End User Insights
The market is divided into hospitals, clinics, and others based on end user. The hospital segment has the biggest market share in 2024. This can be attributable to a big patient pool and a significant demand for improved MG treatment equipment in hospitals. Patient visits for MG diagnosis and treatment have increased as a result of the availability of a diverse range of treatment choices in such facilities. Furthermore, rising investment in cutting-edge healthcare infrastructures is a big contributor to its large market share. The clinic segment held the second-largest share and is likely to maintain that position during the forecast period. With the increased demand for specialized treatments, many patients prefer to visit specialty clinics for a quick diagnosis and successful MG therapy.
Regional Insights
North America has the greatest market share and is expected to lead the market during the projection period. This can be due to the widespread use of immunotherapies and monoclonal antibodies, rising healthcare costs, the presence of established R&D facilities, and advantageous reimbursement scenarios.
The Middle East and Africa are predicted to expand at the quickest CAGR during the projection period. This is due to the rising prevalence of myasthenia gravis in the region, particularly among the elderly, increased awareness, the availability of better diagnostic equipment and therapy choices, and the expansion of healthcare infrastructure.
Market Competitive Landscape
Some of the market's top players, such as Alexion Pharmaceuticals, have the greatest market shares due to the high sales of their flagship medications, Soliris and Prograf. However, generic competition is a significant impediment to market expansion due to the patent loss of some marketed medicines and the availability of low-cost replacements for branded pharmaceuticals on the market. To obtain an advantage over competitors, corporations are implementing methods such as expanding into emerging markets, developing new products, raising awareness, and forming alliances. Furthermore, various market companies are conducting clinical trials to determine the efficacy of the medications for the illness.
Recent Developments:
In October 2023, UCB S.A., a worldwide biopharmaceutical firm, announced that ZILBRYSQ (zilucoplan) has been approved by the US FDA to treat generalized myasthenia gravis (gMG) in people who have anti-acetylcholine receptor (AChR) antibodies.
In September 2023, Recipharm AB teamed with AHEAD THERAPEUTICS S.L. to develop a novel medicine for myasthenia gravis. This agreement helps to increase the manufacturing capacity of myasthenia gravis products.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Treatment, By End User
Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
AbbVie Inc, Alexion Pharmaceutical Inc, Avadel Pharmaceuticals, Plc, Bausch Health Companies Inc, F.Hoffmann-La Roche AG, GlaxoSmithKline Plc, Grifols SA, Novartis, Pfizer, Inc, Shire plc.
Key Topics Covered in the Report
Global Myasthenia Gravis Treatment Market Size (FY'2021-FY'2034)
Overview of Global Myasthenia Gravis Treatment Market
Segmentation of Global Myasthenia Gravis Treatment Market By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
Segmentation of Global Myasthenia Gravis Treatment Market By End User (Hospitals, Clinics, Others)
Statistical Snap of Global Myasthenia Gravis Treatment Market
Expansion Analysis of Global Myasthenia Gravis Treatment Market
Problems and Obstacles in Global Myasthenia Gravis Treatment Market
Competitive Landscape in the Global Myasthenia Gravis Treatment Market
Details on Current Investment in Global Myasthenia Gravis Treatment Market
Competitive Analysis of Global Myasthenia Gravis Treatment Market
Prominent Players in the Global Myasthenia Gravis Treatment Market
SWOT Analysis of Global Myasthenia Gravis Treatment Market
Global Myasthenia Gravis Treatment Market Future Outlook and Projections (FY'2025-FY'2034)
Recommendations from Analyst
According to SPER Market Research, the Global Myasthenia Gravis Treatment Market is estimated to reach USD 5.81 billion by 2034 with a CAGR of 9.25%.
The report includes an in-depth analysis of the Global Myasthenia Gravis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The global Myasthenia Gravis Treatment market was valued at USD 2.4 billion in 2024, and it is expected to rise at a 9.25% CAGR from 2025 to 2034. Myasthenia gravis treatment is being driven by advances in biotechnology, targeted biologic therapies, rising diagnosis rates, increased investment in orphan drugs, favorable regulations, expedited approvals, and an aging population that requires effective long-term management of autoimmune disorders. Meanwhile, the myasthenia gravis treatment industry is constrained by high treatment costs, insufficient reimbursement, limited healthcare infrastructure, lengthy regulatory approvals, and concerns about long-term safety and efficacy, which all limit accessibility, adoption, and consistent growth of therapies across regions.
By Treatment Type Insights
Medications can significantly suppress the immune system and effectively manage the resulting symptoms. Immunotherapies like Soliris (eculizumab) and corticosteroids, as well as immunosuppressive medicines like Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine), are used. The other primary treatment option is surgery, which is the most invasive and typically involves a thymectomy. The thymus deteriorates with age (thymic involution); nonetheless, full absence of the thymus will drastically decrease a patient's immunological response. The monoclonal antibodies segment had the biggest market share and is likely to keep its lead position during the projection period, owing to its high precision in treating myasthenia gravis and improved effectiveness.
By End User Insights
The market is divided into hospitals, clinics, and others based on end user. The hospital segment has the biggest market share in 2024. This can be attributable to a big patient pool and a significant demand for improved MG treatment equipment in hospitals. Patient visits for MG diagnosis and treatment have increased as a result of the availability of a diverse range of treatment choices in such facilities. Furthermore, rising investment in cutting-edge healthcare infrastructures is a big contributor to its large market share. The clinic segment held the second-largest share and is likely to maintain that position during the forecast period. With the increased demand for specialized treatments, many patients prefer to visit specialty clinics for a quick diagnosis and successful MG therapy.
Regional Insights
North America has the greatest market share and is expected to lead the market during the projection period. This can be due to the widespread use of immunotherapies and monoclonal antibodies, rising healthcare costs, the presence of established R&D facilities, and advantageous reimbursement scenarios.
The Middle East and Africa are predicted to expand at the quickest CAGR during the projection period. This is due to the rising prevalence of myasthenia gravis in the region, particularly among the elderly, increased awareness, the availability of better diagnostic equipment and therapy choices, and the expansion of healthcare infrastructure.
Market Competitive Landscape
Some of the market's top players, such as Alexion Pharmaceuticals, have the greatest market shares due to the high sales of their flagship medications, Soliris and Prograf. However, generic competition is a significant impediment to market expansion due to the patent loss of some marketed medicines and the availability of low-cost replacements for branded pharmaceuticals on the market. To obtain an advantage over competitors, corporations are implementing methods such as expanding into emerging markets, developing new products, raising awareness, and forming alliances. Furthermore, various market companies are conducting clinical trials to determine the efficacy of the medications for the illness.
Recent Developments:
In October 2023, UCB S.A., a worldwide biopharmaceutical firm, announced that ZILBRYSQ (zilucoplan) has been approved by the US FDA to treat generalized myasthenia gravis (gMG) in people who have anti-acetylcholine receptor (AChR) antibodies.
In September 2023, Recipharm AB teamed with AHEAD THERAPEUTICS S.L. to develop a novel medicine for myasthenia gravis. This agreement helps to increase the manufacturing capacity of myasthenia gravis products.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Treatment, By End User
Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
AbbVie Inc, Alexion Pharmaceutical Inc, Avadel Pharmaceuticals, Plc, Bausch Health Companies Inc, F.Hoffmann-La Roche AG, GlaxoSmithKline Plc, Grifols SA, Novartis, Pfizer, Inc, Shire plc.
Key Topics Covered in the Report
Global Myasthenia Gravis Treatment Market Size (FY'2021-FY'2034)
Overview of Global Myasthenia Gravis Treatment Market
Segmentation of Global Myasthenia Gravis Treatment Market By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
Segmentation of Global Myasthenia Gravis Treatment Market By End User (Hospitals, Clinics, Others)
Statistical Snap of Global Myasthenia Gravis Treatment Market
Expansion Analysis of Global Myasthenia Gravis Treatment Market
Problems and Obstacles in Global Myasthenia Gravis Treatment Market
Competitive Landscape in the Global Myasthenia Gravis Treatment Market
Details on Current Investment in Global Myasthenia Gravis Treatment Market
Competitive Analysis of Global Myasthenia Gravis Treatment Market
Prominent Players in the Global Myasthenia Gravis Treatment Market
SWOT Analysis of Global Myasthenia Gravis Treatment Market
Global Myasthenia Gravis Treatment Market Future Outlook and Projections (FY'2025-FY'2034)
Recommendations from Analyst
Table of Contents
259 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Myasthenia Gravis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Myasthenia Gravis Treatment Market
- 7. Global Myasthenia Gravis Treatment Market, By Treatment Type (USD Million) 2021-2034
- 7.1. Cholinesterase Inhibitors
- 7.2. Chronic Immunomodulators
- 7.3. Monoclonal Antibodies
- 7.4. Rapid Immunotherapies
- 7.5. Thymectomy
- 7.6. Others
- 8. Global Myasthenia Gravis Treatment Market, By End User (USD Million) 2021-2034
- 8.1. Hospitals
- 8.2. Clinics
- 8.3. Others
- 9. Global Myasthenia Gravis Treatment Market, (USD Million) 2021-2034
- 9.1. Global Myasthenia Gravis Treatment Market Size and Market Share
- 10. Global Myasthenia Gravis Treatment Market, By Region, (USD Million) 2021-2034
- 10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
- 10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
- 10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
- 10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
- 10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America
- 11. Company Profile
- 11.1. AbbVie Inc
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
- 11.2. Alexion Pharmaceutical Inc
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
- 11.3. Avadel Pharmaceuticals, Plc
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
- 11.4. Bausch Health Companies Inc
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
- 11.5. F. Hoffmann-La Roche AG
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
- 11.6. GlaxoSmithKline Plc
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
- 11.7. Grifols SA
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
- 11.8. Novartis
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
- 11.9. Pfizer, Inc
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
- 11.10. Shire plc
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
- 11.11. Others
- 12. Conclusion
- 13. List of Abbreviations
- 14. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
